Citadel Advisors’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $306K | Sell |
22,898
-168,711
| -88% | -$2.25M | ﹤0.01% | 4593 |
|
|
2025
Q1 | $1.95M | Sell |
191,609
-599,500
| -76% | -$6.11M | ﹤0.01% | 2616 |
|
|
2024
Q4 | $12.5M | Buy |
791,109
+86,186
| +12% | +$1.36M | ﹤0.01% | 1189 |
|
|
2024
Q3 | $40.9M | Buy |
704,923
+294,439
| +72% | +$17.1M | 0.01% | 559 |
|
|
2024
Q2 | $18.8M | Sell |
410,484
-39,794
| -9% | -$1.82M | ﹤0.01% | 895 |
|
|
2024
Q1 | $29.8M | Sell |
450,278
-309,890
| -41% | -$20.5M | 0.01% | 697 |
|
|
2023
Q4 | $30.2M | Buy |
760,168
+355,019
| +88% | +$14.1M | 0.01% | 669 |
|
|
2023
Q3 | $12.9M | Buy |
405,149
+77,349
| +24% | +$2.47M | ﹤0.01% | 1000 |
|
|
2023
Q2 | $13.2M | Sell |
327,800
-43,683
| -12% | -$1.76M | ﹤0.01% | 1037 |
|
|
2023
Q1 | $15.9M | Sell |
371,483
-33,988
| -8% | -$1.45M | ﹤0.01% | 990 |
|
|
2022
Q4 | $19.5M | Sell |
405,471
-22,636
| -5% | -$1.09M | ﹤0.01% | 888 |
|
|
2022
Q3 | $16.1M | Buy |
428,107
+73,753
| +21% | +$2.77M | ﹤0.01% | 957 |
|
|
2022
Q2 | $9.79M | Buy |
354,354
+74,193
| +26% | +$2.05M | ﹤0.01% | 1296 |
|
|
2022
Q1 | $15.2M | Buy |
280,161
+3,059
| +1% | +$166K | ﹤0.01% | 1100 |
|
|
2021
Q4 | $16.2M | Buy |
277,102
+2,777
| +1% | +$162K | ﹤0.01% | 1075 |
|
|
2021
Q3 | $10.9M | Buy |
274,325
+156,377
| +133% | +$6.19M | ﹤0.01% | 1370 |
|
|
2021
Q2 | $5.01M | Sell |
117,948
-9,977
| -8% | -$424K | ﹤0.01% | 2146 |
|
|
2021
Q1 | $7.87M | Sell |
127,925
-141,318
| -52% | -$8.7M | ﹤0.01% | 1641 |
|
|
2020
Q4 | $19M | Buy |
+269,243
| New | +$19M | ﹤0.01% | 880 |
|
|
2020
Q3 | – | Sell |
-157,333
| Closed | -$5.9M | – | 5001 |
|
|
2020
Q2 | $5.9M | Buy |
+157,333
| New | +$5.9M | ﹤0.01% | 1410 |
|